Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial

References

• Hallek M. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol 2013;88:803-16
   PubMed Web of Science ®Google Scholar
• Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood 2014;122:3723-34
   Web of Science ®Google Scholar
• Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998;338:1506-14
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomized, open-label, Phase 3 trial. Lancet 2010;376:1164-74
   PubMed Web of Science ®Google Scholar
• Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27(26):4378-84
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Stilgenbauer S, et al. German CLL Study Group (GCLLSG). First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009;27:4378-84
   Google Scholar
• Molica S, Brugiatelli M, Morabito F, et al. Treatment of elderly. patients with chronic lymphocytic leukemia: an unmet clinical need. Exp Rev Hematol 2013;6(4):441-9
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med2014;370(12):1101-10
   PubMed Web of Science ®Google Scholar
• Owen CJ, Stewart DA. Obinutuzumab for B-cell malignancies. Expert Opin Biol Ther 2014;14(8):1197-2205
   PubMed Web of Science ®Google Scholar
• Bologna L, Gotti E, Manganini M, et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011;186(6):3762-9
   PubMed Web of Science ®Google Scholar
• Golay J, Da Roit F, Bologna L, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 2013;122(20):3482-91
   PubMed Web of Science ®Google Scholar
• Robak T. Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia. Future Oncol 2013;9(1):69-91
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Cartron G, Lamy T, et al. Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. Program and abstracts of the 51st American Society of Hematology Annual Meeting; 5–8 December2009. New Orleans, Louisiana: Abstract 884
   Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-556
   PubMed Web of Science ®Google Scholar
• Sehn LH, Assouline SE, Stewart DA, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 2012;119(22):5118-25
   PubMed Web of Science ®Google Scholar
• A study comparing RO5072759 (GA101) 1000 mg versus 2000 mg in patients with previously untreated chronic lymphocytic leukemia (GAGE). Available from: http://clinicaltrials.gov/show/NCT01414205
   Google Scholar
• Flynn JM, Byrd JC, Kipps TJ, et al. Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): results of the phase II GAGE (GAO4768g) trial. J Clin Oncol 2014;32(5s(suppl): abstract 7083
   Google Scholar
• Cartron G, de Guibert S, Dilhuydy MS, et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood 2014;124(14):2196-202
   PubMed Web of Science ®Google Scholar
• Brown JR, O’Brien S, Kingsley CD, et al. Safety and efficacy of obinutuzumab (GA101) with fludarabine/cyclophosphamide (G-FC) or bendamustine (G-B) in the initial therapy of patients with chronic lymphocytic leukemia (CLL): results from the phase 1b galton trial (GAO4779g). Abstract 523 Program and abstracts of the 55th American Society of Hematology Annual Meeting and Exposition. 7–10 December 2013. New Orleans, LA, USA
   Google Scholar
• Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc 1995;43:130-7
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41
   PubMed Web of Science ®Google Scholar
• Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008;49(1):49-56
   PubMed Web of Science ®Google Scholar
• Goede V, Cramer P, Busch R, et al. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica 2014;99(6):1095-100
   PubMed Web of Science ®Google Scholar
• Lee HZ, Miller BW, Kwitkowski VE, et al. U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia. Clin Cancer Res 2014;20(15):3902-7
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Fink AM, Busch R, et al. Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Analysis Of The CLL10 Trial, An International, Randomized Study Of The German CLL Study Group (GCLLSG). Abstract 642 Program and abstracts of the 55th American Society of Hematology Annual Meeting and Exposition. 7–10 December 2013. New Orleans, LA, USA
   Google Scholar
• Cuneo A, Marchetti M, Barosi G, et al. Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. Leuk Res 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Rai K, et al. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential Cancer and Leukemia Group B studies. J Clin Oncol 2013;31:440-7
   PubMed Web of Science ®Google Scholar
• Foà R, Del Giudice I, Cuneo A, et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol 2014;89(5):480-6
   PubMed Web of Science ®Google Scholar
• Hillmen P, Gribben JG, Follows GA, et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study. J Clin Oncol 2014;32(12):1236-41
   PubMed Web of Science ®Google Scholar
• Hillmen P, Robak T, Janssens A, et al. Ofatumumab + chlorambucil versus chlorambucil alone in Patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911). Abstract 528 Program and abstracts of the 55th American Society of Hematology Annual Meeting and Exposition. 7 – 10 December 2013. New Orleans, LA, USA
   Google Scholar
• Tausch E, Beck P, Schlenk RF, et al. NOTCH1 Mutation and Treatment Outcome In CLL Patients Treated With Chlorambucil (Chl) Or Ofatumumab-Chl (O-Chl): Results From The Phase III Study Complement 1 (OMB110911). Abstract 527 Program and abstracts of the 55th American Society of Hematology Annual Meeting and Exposition. 7 – 10 December 2013. New Orleans, LA, USA
   Google Scholar
• Molica S. Highlights in the treatment of chronic lymphocytic leukemia from the 2013 meeting of the American Society of Hematology. Expert Rev Hematol 2014;7(2):187-90
   PubMed Web of Science ®Google Scholar
• Byrd JC, Jones JJ, Woyach JA, et al. Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: impact on the Practicing Clinician. J Clin Oncol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371(3):213-23
   PubMed Web of Science ®Google Scholar
• Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2014;15(10):1090-9
   PubMed Web of Science ®Google Scholar
• Jaglowski SM, Jones JA, Flynn JM, et al. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. J Clin Oncol 2012;30(418s(suppl):abstract 6508
   Google Scholar
• Brown JR, Barrientos JC, Barr PM, et al. Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL: Final results of a phase 1b study. Blood 2013;122:abstract 525
   Web of Science ®Google Scholar